Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
search
Join
FREE
You must accept all conditions before being able to view the post
Continue
EUR
USA
EUR
USA
Therapy Area
Allergy & Immunology
Cardiology
Dermatology
Diabetes
Flagship Journal
Gastroenterology
General Healthcare
Hematology
Hepatology
Innovations
Interventional Cardiology
Microbiology & Infectious Diseases
Nephrology
Neurology
Oncology
Radiology
Reproductive Health
Respiratory
Rheumatology
Urology
Podcasts
Journals
Webinars
Collaborate
EMJ Media Pack
AMJ Media Pack
Editorial Enquiries
Contributors & Authors
Submit a Paper
Media Partners
Pharma Partners
EMJ Interactive
About
About
EQOH
Careers
Contact Us
EMJ Gold
Join
FREE
Pharma News, Views & Analysis
Filter
News
Articles
Podcasts
Infographics
Advertise With Us
Advertise With Us
ViiV, Roche and Gilead lead pharma patient group rankings
ViiV leads the 2024/25 pharma company reputation rankings, with the PatientView report also finding ways in which the industry can improve.
Read more
Europe's biopharma SMEs need urgent support, warns EFPIA
Europe must act urgently to back small and medium-sized enterprises (SMEs) in the biopharmaceutical sector, says the EFPIA.
First anti-TFPI for haemophilia approved in EU
Pfizer’s anti-tissue factor pathway inhibitor has been approved for the treatment of haemophilia A & B by the European Commission.
FDA greenlights UCB’s IL-17 inhibitor for HS
The novel IL-17A and IL-17F inhibitor has been approved the treatment of moderate to severe hidradenitis suppurativa, a chronic and painful skin disease.
Novartis takes the top spot in 2024 Access to Medicine Index
Novartis has claimed the top spot in the 2024 Access to Medicine Index, displacing GSK after 16 consecutive years at the top.
Revisto raises $4m to streamline pharma compliance with AI
Revisto has raised $4m in seed funding to simplify the pharmaceutical industry’s marketing compliance processes using AI.
FDA approves first gene therapy delivered directly to the brain
Discover how PTC Therapeutics’ treatment for a rare and fatal genetic disorder called aromatic l-amino acid decarboxylase (AADC) deficiency reached approval
Europe’s pharma R&D productivity grows, but falls behind US and China
Europe’s pharmaceutical research and development sector is in a tight spot as new data reveals that R&D spending isn’t keeping up with global competitors.
AstraZeneca bets big on US, pledges to invest $3.5bn
Discover how AZ’s capital investment is set to expand its US research and manufacturing capabilities by the end of 2026.
Loading posts...
« Previous
1
…
8
9
10
11
12
…
26
Next »
We’ve noticed you’re accessing
from
North/South America.
View
View